Clinical trial
Docetaxel in Locally Advanced Gastric Adenocarcinoma
NCT00343239 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00343239 |
|---|---|
| Title | Docetaxel in Locally Advanced Gastric Adenocarcinoma |
| Official title | Docetaxel, Cisplatin and Fluorouracil Combination in the Neoadjuvant Treatment of Locally Advanced Gastric Adenocarcinoma : Phase II Clinical Study |
| Acronym | NEOTAX |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stomach Neoplasms |
| Intervention type | Drug |
| Interventions | Docetaxel, Cisplatin, Fluorouracil |
| Enrollment | 59 |
| Start date | Jun 1, 2006 |
| Primary completion | Mar 1, 2012 |
| Completion | Mar 1, 2012 |
| First posted | Jun 22, 2006 |
| Last update posted | Nov 4, 2014 |
| Countries | Turkey (Türkiye) |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: